Lantern Pharma Inc (LTRN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.91+2.14%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Maintain or improve earnings trajectory: EPS -0.57 vs target -0.38.
Lantern Pharma uses AI and genomics to develop cancer therapies. The company has beaten earnings estimates multiple times, including in Q4 2025 and Q1 2026. Management is progressing on creating an independent AI business entity, scoring 66% on this goal. Despite losses, the company shows stable management and positive operational momentum.
Lantern Pharma remains loss-making with negative EPS of -0.38 in Q3 2026 and -1.51 for full year 2026. The company raised capital through unregistered equity sales and debt issuance, signaling cash needs. There is no revenue forecast and no clear path to profitability yet.
The market is correcting with a 9.2% one-day drop but no clear consensus revenue or EPS growth is priced in. Estimates show continued losses through 2027. Our view is cautious given the lack of revenue and ongoing losses despite earnings beats.
Breaks if: Progress score falls below 50% or project stalls
Separate the AI platform assets and personnel into an independent business entity to access dedicated funding and distinct valuation.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but is focusing on advancing its oncology drug programs and commercializing its AI platform, which could drive future growth.
The market seems to be pricing in a significant amount of uncertainty due to LTRN's high risk and loss-making status. Recent earnings beats suggest some positive sentiment, but the overall expectations remain cautious given the company's financial challenges.
Management is making progress with its oncology programs and AI platform, which could improve fundamentals over the multi-year horizon. However, the recent change in risk label to high indicates that volatility may persist, especially in a challenging economic environment.
The thesis hinges on the company's ability to advance its clinical programs and successfully commercialize its AI platform. Additionally, external factors such as sector performance and economic conditions will play a critical role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company announced plans for an AI spin-out. This move aims to create an independent AI business entity. The bladder cancer trial received clearance from the EMA. This supports growth in bladder cancer treatment. The company also advanced its AI-driven pipeline for oncology drugs.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Management publicly launched withZeta.ai in 2026-Q1 and by 2026-Q2 had established Open Medicine AI as a separate company with board-approved licenses. This separation aims to unlock dedicated funding and valuation distinct from clinical drug development. The trajectory is delivering on the planned AI business separation.
“Open Medicine AI established as a separate company with board-approved commercial licensing agreements.”
“Strategic plan to create an independent entity composed of withZeta.ai assets.”
Breaks if: Repeated large equity sales causing heavy dilution
Breaks if: EPS loss worsens beyond -0.38 in Q3 2026
LTRN's multi-year view remains intact, supported by management's focus on key priorities, but it faces high risks and uncertainties. Not investment advice.